Showing 31 to 40 of 322 resources

Published in July 2019 this review summarizes the evidence for interventions to increase case-finding and linkage to care for hepatitis C-infected patients, in order to support commissioning and provision of evidence-based interventions as part of efforts to achieve hepatitis C (HCV) elimination as a major public health threat in the UK.

This report from the Correlation European Harm Reduction Network is based on a telephone survey conducted in September and October 2018 with representatives of harm reduction services and NGOs that offer low-threshold services to drug users.

On Thursday 4th July, HCV Action held a National Hepatitis C ODN Stakeholder Event, in partnership with the British Viral Hepatitis Group. The event - HCV Action's biggest to date - brought ODN representatives together to discuss the opportunities and challenges associated with the recently-announced NHS England elimination deal.

This report provides a summary of the the breakout sessions held during the HCV Action & British Viral Hepatitis Group National Hepatitis C ODN Stakeholder Event, which took place at the University of Warwick on 4th July 2019. The breakout sessions were held in two parts, the first focusing on problem identification and the second on identifying solutions, and focused on the following topics: community outreach; reaching ethnic minority groups; treating in prisons; and engaging with local commissioners & other partners.

This Health Protection Scotland report outlines that there were 1,423 new diagnoses of hepatitis C antibody-positivity in Scotland in 2018, the lowest number of new hepatitis C antibody diagnoses in Scotland since 1996. It is estimated that approximately 21,000 individuals were living with chronic hepatitis C infection in Scotland by the end of 2018 and approximately 10,500 of these have been diagnosed. A total of 2,609 individuals were initiated onto hepatitis C treatment during financial year 2018/19.

This report from the European Monitoring Centre for Drugs and Drug Addiction provides an overview of infectious disease surveillance data, outbreak investigations, and prevention and control measures among people who inject drugs in Europe up to February 2019, including viral hepatitis.

This study evaluates peer-supported screening as a model of active HCV case finding within prisons with a secondary aim to describe the HCV cascade among those infected including linkage to care and treatment outcomes. The study was carried out in a medium-security Irish male prison with over 500 inmates. The authors conclude that peer-supported screening is an effective active HCV case-finding model to find and link prisoners with untreated active HCV infection to HCV care.

This document from Public Health England provides information for GPs on the ongoing Infected Blood Inquiry, chaired by Sir Brian Langstaff. The document covers: why there is an Infected Blood Inquiry; what to advise if your patient thinks that they received blood in the 1970s/1980s; what to do if your patient is hepatitis C positive and is concerned a past transfusion

Following an inquiry into hepatitis C, the Welsh Assembly Health, Social Care and Sport Committee published this report. The report makes four main recommendations to the Welsh Government: that the Welsh Government produces a comprehensive national elimination strategy for hepatitis C, with clear ambitious targets, and workforce planning built in, and provides sustainable funding until elimination is achieved; implementation of a targeted awareness raising campaign to reach out to at risk communities; to write to Local Health Board

The World Health Organisation has published its mid-term report on progress towards implementing the 'Global health sector strategies on HIV, viral hepatitis and sexually transmitted infections'. The UK signed up to the 'Global health sector strategy on viral hepatitis 2016-21', committing to eliminating hepatitis C by 2030.
The report highlights the need to strengthen data and update hepatitis data more regularly. It states that global targets for reducing mortality from viral hepatitis will not be met 'without massively accelerating universal access to testing' and treatment.